Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > Today’s trading
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(7)
•••
Comment by archeo753on Feb 04, 2021 5:46pm
95 Views
Post# 32479490

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Today’s trading

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Today’s tradingFor some reason this makes me want to go listen to "Fifty-Mission Cap" at maximum volume.  Thanks.

jfm1330 wrote: I am repeating here that Thera as a company has a credibility problem because of a long history of underachievment. They never made it for real. Yes they got approvals from FDA, but always followed by commercial underperformance. It is not the new shinny object with no history.

They are like a team that just made the playoffs a couple times in 27 years, only to be thrown out each time in four games in the first round. Even hiring a new GM was not enough to change the perception and this GM just made a questionable trade for a bunch of draft picks. Many season tickets holder are not happy...


archeo753 wrote:
jeffm34 wrote: If anyone here is still wondering why some of us are still complaining about the financing all you have to do is look at the trading today. 


Hard not to feel like the ugly step sister TH up 15% on news IMV up 14.5% on no news!?? 
 




<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities